Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology
Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS, which enables the unbiased identification of cell surface receptors for many types of ligands, such as peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place under near-physiological conditions on native tissues and cells, without the need for genetic manipulations.
Dualsystems Biotech AG Press Release For immediate distribution
Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand
Receptor Capture Technology
Schlieren/Zurich, Switzerland – June 24, 2013 – Dualsystems Biotech has licensed an innovative
technology to discover cell-surface receptors for a vast range of ligands of interest.
LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS, which
enables the unbiased identification of cell surface receptors for many types of ligands, such as
peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place
under near-physiological conditions on native tissues and cells, without the need for genetic
manipulations.
Dualsystems Biotech plans to introduce the LRC technology in a user-friendly reagent kit format and
as a fully customized service to interested users within the pharma, biotech and agro industry as well
as to academic research groups.
More details on Ligand Receptor Capture technology will soon be launched on the company’s
website www.dualsystems.com. Interested parties may contact Dualsystems by e-mail to
info@dualsystems.com, call +41 44 738 50 00, fax +41 44 738 50 05 or write to Dualsystems Biotech
AG, Grabenstrasse 11a, Schlieren CH-8952, Switzerland.
